OBI Pharma Inc. to attend The 37th Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2019
Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study by Ministry of Health of UkraineFebruary 20, 2019
- Date of occurrence of the event: Feb 13, 2019
- Company name: OBI Pharma Inc.
- Relationship to the Company (please enter “head office” or “subsidiaries”): Head office
- Reciprocal shareholding ratios: N/A
- Name of mass media: Page C5 of Economy Daily News on Feb 13, 2019
- Content reported: News article by Economy Daily News regarding the collaborative publication by OBI Pharma Inc. and Academia Sinica
- Cause of occurrence: Clarification on news article
- Countermeasures: Information regarding the press release has been made available to the public on Feb 12, 2019. For more detail, please visit OBI’s corporate website at http://www.obipharma.com. Publication related information can be found on PNAS’s official website at https://www.pnas.org/content/early/2019/02/08/1816946116.
- Any other matters that need to be specified: New drug development is a long process associated with high costs. It is not a guaranteed success, which may increase the risk of investment. Investors shall make prudent judgments and investments.